Skip to main content

Advertisement

SpringerLink
Log in

Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Fibrosis is the only histological feature reflecting the severity and prognosis of nonalcoholic steatohepatitis (NASH). We aim to explore novel genes associated with fibrosis progression in NASH.

Methods

Two human RNA-seq datasets were downloaded from the public database. Weighted gene co-expression network analysis (WGCNA) was used to identify their co-expressed modules and further bioinformatics analysis was performed to identify hub genes within the modules. Finally, based on two single-cell RNA-seq datasets from mice and one microarray dataset from human, we further observed the expression of hub genes in different cell clusters and liver tissues.

Results

7 hub genes (SPP1, PROM1, SOX9, EPCAM, THY1, CD34 and MCAM) associated with fibrosis progression were identified. Single-cell RNA-seq analysis revealed that those hub genes were expressed by different cell clusters such as cholangiocytes, natural killer (NK) cells, and hepatic stellate cells (HSCs). We also found that SPP1 and CD34 serve as markers of different HSCs clusters, which are associated with inflammatory response and fibrogenesis, respectively. Further study suggested that SPP1, SOX9, MCAM and THY1 might be related to NASH-associated hepatocellular carcinoma (HCC). Receiver operating characteristic (ROC) analysis showed that the high expression of these genes could well predict the occurrence of HCC. At the same time, there were significant differences in metabolism-related pathway changes between different HCC subtypes, and SOX9 may be involved in these changes.

Conclusions

The present study identified novel genes associated with NASH fibrosis and explored their effects on fibrosis from a single-cell perspective that might provide new ideas for the early diagnosis, monitoring, evaluation, and prediction of fibrosis progression in NASH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data availability

Data were collected from the GEO database.

References

  1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109

    Article  PubMed  Google Scholar 

  2. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S (2020) Nonalcoholic steatohepatitis: a review. JAMA 323(12):1175–1183. https://doi.org/10.1001/jama.2020.2298

    Article  CAS  PubMed  Google Scholar 

  3. Ciardullo S, Grassi G, Mancia G, Perseghin G (2021) Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. https://doi.org/10.1097/meg.0000000000002299

    Article  PubMed Central  Google Scholar 

  4. Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP (2021) Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. J Endocrinol Invest 44(9):1879–1889. https://doi.org/10.1007/s40618-021-01501-y

    Article  CAS  PubMed  Google Scholar 

  5. Schwabe RF, Tabas I, Pajvani UB (2020) Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158(7):1913–1928. https://doi.org/10.1053/j.gastro.2019.11.311

    Article  CAS  PubMed  Google Scholar 

  6. Zhu C, Tabas I, Schwabe RF, Pajvani UB (2021) Maladaptive regeneration—the reawakening of developmental pathways in NASH and fibrosis. Nat Rev Gastroenterol Hepatol 18(2):131–142. https://doi.org/10.1038/s41575-020-00365-6

    Article  PubMed  Google Scholar 

  7. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149(2):389–97.e10. https://doi.org/10.1053/j.gastro.2015.04.043

    Article  PubMed  Google Scholar 

  8. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quiñones Sanz M, Conde-Martin AF, De Boer B, McLeod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-Gomez M (2018) Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 155(2):443-457.e17. https://doi.org/10.1053/j.gastro.2018.04.034

    Article  PubMed  Google Scholar 

  9. Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377(21):2063–2072. https://doi.org/10.1056/NEJMra1503519

    Article  CAS  PubMed  Google Scholar 

  10. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF (2021) A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385(17):1547–1558. https://doi.org/10.1056/NEJMoa2036205

    Article  CAS  PubMed  Google Scholar 

  11. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. https://doi.org/10.3390/metabo11020073

    Article  PubMed  PubMed Central  Google Scholar 

  12. Morieri ML, Targher G, Lapolla A, D’Ambrosio M, Tadiotto F, Rigato M, Frison V, Paccagnella A, Simioni N, Avogaro A, Fadini GP (2021) Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutr Metab Cardiovasc Dis 31(12):3474–3483. https://doi.org/10.1016/j.numecd.2021.08.049

    Article  CAS  PubMed  Google Scholar 

  13. Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. https://doi.org/10.1186/1471-2105-9-559

    Article  PubMed  PubMed Central  Google Scholar 

  14. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41:D991–D995. https://doi.org/10.1093/nar/gks1193

    Article  CAS  PubMed  Google Scholar 

  15. Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM (2020) Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aba4448

    Article  PubMed  Google Scholar 

  16. Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM (2021) Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 75(4):865–878. https://doi.org/10.1016/j.jhep.2021.04.049

    Article  CAS  PubMed  Google Scholar 

  17. Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, Hill J, Boustany-Kari CM, Doerner JF, Rippmann JF, Chung RT, Ho Sui SJ, Simon E, Corey KE (2021) Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 11(1):18045. https://doi.org/10.1038/s41598-021-96966-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284–287. https://doi.org/10.1089/omi.2011.0118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Thomas PD, Mi H, Lewis S (2007) Ontology annotation: mapping genomic regions to biological function. Curr Opin Chem Biol 11(1):4–11. https://doi.org/10.1016/j.cbpa.2006.11.039

    Article  CAS  PubMed  Google Scholar 

  20. Kanehisa M (2019) Toward understanding the origin and evolution of cellular organisms. Protein Sci 28(11):1947–1951. https://doi.org/10.1002/pro.3715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D’Eustachio P (2020) The reactome pathway knowledgebase. Nucleic Acids Res 48(D1):D498-d503. https://doi.org/10.1093/nar/gkz1031

    Article  CAS  PubMed  Google Scholar 

  22. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45(D1):D362-d368. https://doi.org/10.1093/nar/gkw937

    Article  CAS  PubMed  Google Scholar 

  23. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ (2019) Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 18(2):623–632. https://doi.org/10.1021/acs.jproteome.8b00702

    Article  CAS  PubMed  Google Scholar 

  24. Zhao X, Wu S, Fang N, Sun X, Fan J (2020) Evaluation of single-cell classifiers for single-cell RNA sequencing data sets. Brief Bioinform 21(5):1581–1595. https://doi.org/10.1093/bib/bbz096

    Article  CAS  PubMed  Google Scholar 

  25. Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C, Luo T, Xu L, Liao G, Yan M, Ping Y, Li F, Shi A, Bai J, Zhao T, Li X, Xiao Y (2019) Cell Marker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res 47(D1):D721-d728. https://doi.org/10.1093/nar/gky900

    Article  CAS  PubMed  Google Scholar 

  26. MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, Manuel J, Khuu N, Echeverri J, Linares I, Gupta R, Cheng ML, Liu LY, Camat D, Chung SW, Seliga RK, Shao Z, Lee E, Ogawa S, Ogawa M, Wilson MD, Fish JE, Selzner M, Ghanekar A, Grant D, Greig P, Sapisochin G, Selzner N, Winegarden N, Adeyi O, Keller G, Bader GD, McGilvray ID (2018) Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun 9(1):4383. https://doi.org/10.1038/s41467-018-06318-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD (2019) Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell 75(3):644-660.e5. https://doi.org/10.1016/j.molcel.2019.07.028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Deczkowska A, David E, Ramadori P, Pfister D, Safran M, At The B, Giladi A, Jaitin DA, Barboy O, Cohen M, Yofe I, Gur C, Shlomi-Loubaton S, Henri S, Suhail Y, Qiu M, Kam S, Hermon H, Lahat E, Ben Yakov G, Cohen-Ezra O, Davidov Y, Likhter M, Goitein D, Roth S, Weber A, Malissen B, Weiner A, Ben-Ari Z, Heikenwälder M, Elinav E, Amit I (2021) XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med 27(6):1043–1054. https://doi.org/10.1038/s41591-021-01344-3

    Article  CAS  PubMed  Google Scholar 

  29. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. https://doi.org/10.1186/1471-2105-12-77

    Article  PubMed  PubMed Central  Google Scholar 

  30. Thul PJ, Lindskog C (2018) The human protein atlas: a spatial map of the human proteome. Protein Sci 27(1):233–244. https://doi.org/10.1002/pro.3307

    Article  CAS  PubMed  Google Scholar 

  31. Li J, Xie L, Xie Y, Wang F (2020) Bregmannian consensus clustering for cancer subtypes analysis. Comput Methods Programs Biomed. https://doi.org/10.1016/j.cmpb.2020.105337

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, Zhang Q, Chong Y, Hu B (2021) HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Brief Bioinform. https://doi.org/10.1093/bib/bbaa427

    Article  PubMed  Google Scholar 

  33. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47. https://doi.org/10.1093/nar/gkv007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184(10):2537–2564. https://doi.org/10.1016/j.cell.2021.04.015

    Article  CAS  PubMed  Google Scholar 

  35. Teli MR, James OF, Burt AD, Bennett MK, Day CP (1995) The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22(6):1714–1719

    Article  CAS  Google Scholar 

  36. Ciardullo S, Ronchetti C, Muraca E, Oltolini A, Perra S, Bianconi E, Zerbini F, Cannistraci R, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G (2020) Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. J Endocrinol Invest 43(7):1019–1026. https://doi.org/10.1007/s40618-020-01188-7

    Article  CAS  PubMed  Google Scholar 

  37. Barchetta I, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, Chiappetta C, Bertoccini L, Tramutola A, Labbadia G, Di Cristofano C, Silecchia G, Leonetti F, Cavallo MG (2021) Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. J Endocrinol Invest 44(5):979–988. https://doi.org/10.1007/s40618-020-01392-5

    Article  CAS  PubMed  Google Scholar 

  38. Filardi T, Panimolle F, Tiberti C, Crescioli C, Lenzi A, Pallotta N, Morano S (2021) Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults. J Endocrinol Invest 44(1):105–110. https://doi.org/10.1007/s40618-020-01274-w

    Article  CAS  PubMed  Google Scholar 

  39. Alipoor B, Nikouei S, Rezaeinejad F, Malakooti-Dehkordi SN, Sabati Z, Ghasemi H (2021) Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. J Endocrinol Invest 44(10):2015–2041. https://doi.org/10.1007/s40618-021-01559-8

    Article  CAS  PubMed  Google Scholar 

  40. Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P (2005) A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci 50(6):1130–1135. https://doi.org/10.1007/s10620-005-2719-1

    Article  CAS  PubMed  Google Scholar 

  41. Chiba M, Sasaki M, Kitamura S, Ikeda H, Sato Y, Nakanuma Y (2011) Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. J Clin Pathol 64(7):564–570. https://doi.org/10.1136/jcp.2011.090175

    Article  PubMed  Google Scholar 

  42. Natarajan SK, Ingham SA, Mohr AM, Wehrkamp CJ, Ray A, Roy S, Cazanave SC, Phillippi MA, Mott JL (2014) Saturated free fatty acids induce cholangiocyte lipoapoptosis. Hepatology 60(6):1942–1956. https://doi.org/10.1002/hep.27175

    Article  CAS  PubMed  Google Scholar 

  43. Yovchev MI, Locker J, Oertel M (2016) Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes. J Hepatol 64(6):1348–1357. https://doi.org/10.1016/j.jhep.2016.01.036

    Article  PubMed  PubMed Central  Google Scholar 

  44. Song Z, Chen W, Athavale D, Ge X, Desert R, Das S, Han H, Nieto N (2021) Osteopontin takes center stage in chronic liver disease. Hepatology 73(4):1594–1608. https://doi.org/10.1002/hep.31582

    Article  PubMed  Google Scholar 

  45. Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102(4):912–924. https://doi.org/10.1002/jcb.21558

    Article  CAS  PubMed  Google Scholar 

  46. Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF (2018) Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun 2(11):1344–1355. https://doi.org/10.1002/hep4.1237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Komori J, Hatano E, Kawaguchi Y, Uemoto S (2016) SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep. https://doi.org/10.1038/srep30489

    Article  PubMed  PubMed Central  Google Scholar 

  48. Wang C, Deng J, Deng H, Kang Z, Huang Z, Ding Z, Dong L, Chen J, Zhang J, Zang Y (2020) A novel Sox9/lncRNA H19 axis contributes to hepatocyte death and liver fibrosis. Toxicol Sci 177(1):214–225. https://doi.org/10.1093/toxsci/kfaa097

    Article  CAS  PubMed  Google Scholar 

  49. Kordes C, Sawitza I, Müller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Häussinger D (2007) CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 352(2):410–417. https://doi.org/10.1016/j.bbrc.2006.11.029

    Article  CAS  PubMed  Google Scholar 

  50. Fenlon M, Short C, Xu J, Malkoff N, Mahdi E, Hough M, Glazier A, Lee C, Asahina K, Wang KS (2020) Prominin-1-expressing hepatic progenitor cells induce fibrogenesis in murine cholestatic liver injury. Physiol Rep 8(14):e14508. https://doi.org/10.14814/phy2.14508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zagory JA, Fenlon M, Dietz W, Zhao M, Nguyen MV, Trinh P, Adoumie M, Park A, Xu J, Mahdi E, Glazier A, Malkoff N, Mavila N, Wang KS (2019) Prominin-1 promotes biliary fibrosis associated with biliary atresia. Hepatology 69(6):2586–2597. https://doi.org/10.1002/hep.30550

    Article  CAS  PubMed  Google Scholar 

  52. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, Lanuti M, Tanabe KK (2010) Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. https://doi.org/10.1186/1471-230x-10-79

    Article  PubMed  PubMed Central  Google Scholar 

  53. Huang L, Yang Y, Yang F, Liu S, Zhu Z, Lei Z, Guo J (2018) Functions of EpCAM in physiological processes and diseases (review). Int J Mol Med 42(4):1771–1785. https://doi.org/10.3892/ijmm.2018.3764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Zhang Z, Wen H, Weng J, Feng L, Liu H, Hu X, Zeng F (2019) Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway. Cell Cycle 18(18):2239–2254. https://doi.org/10.1080/15384101.2019.1642067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Rookmaaker MB, Verhaar MC, Loomans CJ, Verloop R, Peters E, Westerweel PE, Murohara T, Staal FJ, van Zonneveld AJ, Koolwijk P, Rabelink TJ, van Hinsbergh VW (2005) CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol 25(9):1843–1850. https://doi.org/10.1161/01.Atv.0000177808.92494.14

    Article  CAS  PubMed  Google Scholar 

  56. Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD (2011) Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol 35(9):1400–1404. https://doi.org/10.1097/PAS.0b013e3182254283

    Article  PubMed  PubMed Central  Google Scholar 

  57. Rege TA, Hagood JS (2006) Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. Faseb j 20(8):1045–1054. https://doi.org/10.1096/fj.05-5460rev

    Article  CAS  PubMed  Google Scholar 

  58. Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7):397–411. https://doi.org/10.1038/nrgastro.2017.38

    Article  CAS  PubMed  Google Scholar 

  59. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134(4):657–667. https://doi.org/10.1016/j.cell.2008.06.049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Katsumata LW, Miyajima A, Itoh T (2017) Portal fibroblasts marked by the surface antigen Thy1 contribute to fibrosis in mouse models of cholestatic liver injury. Hepatol Commun 1(3):198–214. https://doi.org/10.1002/hep4.1023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zheng J, Wu H, Zhang Z, Yao S (2021) Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease. Hereditas 158(1):31. https://doi.org/10.1186/s41065-021-00196-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Joshkon A, Heim X, Dubrou C, Bachelier R, Traboulsi W, Stalin J, Fayyad-Kazan H, Badran B, Foucault-Bertaud A, Leroyer AS, Bardin N, Blot-Chabaud M (2020) Role of CD146 (MCAM) in physiological and pathological angiogenesis-contribution of new antibodies for therapy. Biomedicines. https://doi.org/10.3390/biomedicines8120633

    Article  PubMed  PubMed Central  Google Scholar 

  63. Hintermann E, Christen U (2019) The many roles of cell adhesion molecules in hepatic fibrosis. Cells. https://doi.org/10.3390/cells8121503

    Article  PubMed  PubMed Central  Google Scholar 

  64. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021

    Article  PubMed  Google Scholar 

  65. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S (2017) Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67(6):1265–1273. https://doi.org/10.1016/j.jhep.2017.07.027

    Article  PubMed  Google Scholar 

  66. Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G (2022) Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. https://doi.org/10.1007/s40618-022-01755-0

    Article  PubMed  Google Scholar 

  67. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1):125–172. https://doi.org/10.1152/physrev.00013.2007

    Article  CAS  PubMed  Google Scholar 

  68. Altamirano-Barrera A, Barranco-Fragoso B, Méndez-Sánchez N (2017) Management strategies for liver fibrosis. Ann Hepatol 16(1):48–56. https://doi.org/10.5604/16652681.1226814

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We want to thank and acknowledge all participants of this study and the technical support provided by the Affiliated Hospital of Jiangsu University.

Funding

This work was supported by the National Natural Science Foundation of China (81870548, 81570721), the Social Development Project of Jiangsu Province (BE2018692), the Natural Science Foundation of Jiangsu Province, China (BK20191222, BK20151331), the High Caliber Medical Personnel Foundation of Jiangsu Province (LGY2016053), the Six Talent Peaks Project in Jiangsu Province (2015-WSN-006), and the Fifth “169 project” Scientific Research Project of Zhenjiang City, Jiangsu Province.

Author information

Author notes

  1. Z. Wang, Z. Zhao and Y. Xia contributed equally to this work.

Authors and Affiliations

  1. Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China

    Z. Wang, Z. Zhao, Y. Xia, Z. Cai, C. Wang, Y. Shen, R. Liu, H. Qin, J. Jia & G. Yuan

Authors
  1. Z. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z. Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to J. Jia or G. Yuan.

Ethics declarations

Conflicts of interest

The authors declare that they have no competing interests.

Ethics approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Zhao, Z., Xia, Y. et al. Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH). J Endocrinol Invest 45, 1379–1392 (2022). https://doi.org/10.1007/s40618-022-01773-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-022-01773-y

Keywords

Search

Navigation